gbola amusa md cfa head hc research
sale trade et
sale trade et
viral news genet medicin biib-nit continu flurri aav activ
highlight week march march unrat nightstar neutral announc
agreement acquir nightstar mm repres premium
trade vwap per share confirm publish view interest compani big biopharma
post-poc aav-bas gene therapi gt compani rel free exist big biopharma partnership nightstar
alreadi pair trade publish nite acquisit announc went long basket buy-
rate unpartn qualiti post-poc aav-bas gt companiesnam bold nite qure rgnxagainst
nbi downgrad nite neutral price move deal announc buy
report posit top-line data on-going phase envis trial rnai therapeut givosiran
acut hepat porphyria ahp studi met primari endpoint portion secondari endpoint efficaci
though safeti concern imbal seriou advers event remain nonetheless see givosiran
approv risk/benefit profil given efficaci level unmet medic need fda commission
scott gottlieb announc resign march expect step month
departur impact fda plan initi support innov cell gene therapi open question
look forward march compani report result buy march
edt selecta bioscienc unrat march edt march american colleg cardiolog
annual meet take place new orlean unrat present poster
aav-bas gt program danon diseas
weekli price move figur vivo genet medicin aav srna vivo gene edit
upcom chardan genet medicin event contact chardan rsvp
march chardan sponsor gene therapi genom edit summit host orphan
march chardan sponsor arm cell gene therapi investor day new york citi
april chardan sponsor arm meet mediterranean barcelona
gene express resign fda commission gottlieb affect sector
pleas refer import disclosur inform regul analyst certif found page report
march fda commission scott gottlieb announc resign fda effect month
take biotech sector surpris interview washington dr gottlieb serv fda
commission sinc may cite desir spend time famili reason behind departur
current unclear succeed gottlieb post extent chang impact fda polici move
forward review research note fda support promis gene therapi look
establish new polici framework theme continu throughout fda issu draft
guidanc juli gt hemophilia retin diseas rare diseas well updat prior guidanc
retrovirus long-term follow gottlieb fda made sever gestur facilit streamlin
develop advanc therapi support elimin recombin dna advisori committe
rac review gene therapi clinic trial explain octob new england journal medicin public
publish nih director franci collin
addit commission gottlieb tenur saw us approv number genet medicin car-t
therapi kymriah yescarta aav-bas gt luxturna rnai therapeut onpattro regulatori
design support acceler develop genet medicin also seen uptick period
see figur along introduct rmat design guidanc fda
advanc cell gene therapi anticip januari commission gottlieb
director center biolog evalu research cber fda peter mark releas statement
outlin fda plan front plan includ addit individu expand capac evalu
cell gene therapi well issu addit clinic guidanc document specif indic
manufactur cell-bas therapi innov clinic trial design
expect better visibl commission gottlieb departur may impact initi come week
nite buy acquisit confirm thesi see pair trade march amusa
nightstar enter agreement acquir unrat mm
repres premium trade vwap per share
see news confirmatori view big-biopharma-rel busi develop activ like
qualiti unpartn post-poc aav gene therapi gt compani march open pair trade
go long basket gt compani characterist bold nite qure nbi
qure buy pt progress last month march amusa
increas uniqur price target updat model incorpor progress made
last month particularli posit data uniqur phase iib dose-confirm trial
hemophilia advanc multipl preclin program highlight compani day
updat price target reflect sever updat model increas sale estim
bn bn base increas project uniqur share hemophilia hemb genet
medicin market probabl success increas pipelin hema huntington
diseas sale estim mm bn base preclin progress roll
dcf forward incorpor result bring uniqur closer model profit
nite downgrad neutral stock acquisit price march amusa
downgrad nightstar therapeut neutral announc acquisit compani trade
announc takeout price market close march saw limit scope
out-performance therefor downgrad nite buy neutral
buy underappreci gt compani march amusa
krystal biotech announc offici inaugur new cgmp facil ancori facil
highlight high convict krystal given
design support clinic commerci manufactur compani lead asset gt
 in-hous manufactur on-lin facil develop
 transit post-poc statu posit initi phase i/ii data dystroph epidermolysi bullosa
deb top-line phase ii data anticip
 krystal uniqu platform believ attract big biopharma player
posit top line data phase studi givosiran ahp march naka
page
march alnylam pharmaceut report posit top-lin result phase envis trial
rnai therapeut givosiran acut hepat porphyria ahp
studi met primari efficaci endpoint reduct annual rate composit porphyria attack
month well secondari endpoint biomark reduct lower urinari aminolevulin acid ala level
certain clinic metric month
howev studi miss secondari endpoint includ measur pain fatigu month
safeti alnylam report seriou advers event sae givosiran vs placebo-
treat patient similar ratio sae rate respect report septemb interim
analysi addit new advers event chronic kidney diseas report givosiran patient despit
safeti signal manag note elig envis patient chosen enrol open-
believ envis data support approv risk/benefit profil givosiran given demonstr
efficaci given sever ahp diseas
abu buy updat pipelin program march naka
arbutu biopharma report result along updat guidanc hbv program compani
current enrol hbv patient phase ia/ib studi capsid inhibitor expect report
result around end result posit arbutu plan advanc phase ii dose-find
trial combin approv nucleosid analog na
arbutu addit remain track begin phase ia/ib trial subcutan galnac-bas sirna
agent healthi volunt hbv patient compani anticip result trial
posit evalu combin approv na
believ progress updat across pipelin could serv valu creation event next month
genet medicin news march march
nite neutral announc agreement acquir unrat march
buy appoint julian gangolli board director march
unrat initi piii trial dna-bas immuno-tx hpv cervic cancer march
syngenta privat publish crispr strategi edit commerci crop march
etherna immunotherapi privat complet enrol pib studi adj melanoma march
xbio unrat acquir xcart platform develop person neoantigen-target car-t march
 miami publish aav-bas deliveri anti-hiv mab suppress viru nhp march
studi rhesu macaqu chronic shiv treat aav vector encod broadli neutral
monoclon antibodi mab hiv although author note anti-drug antibodi respons limit mab
deliveri anim maintain transgen antibodi express year correspond reduct
plasma viremia undetect level support proof concept approach gener function cure
unrat current evalu analog approach chikungunya viru system deliveri
mrna encod antibodi current phase clinic trial healthi adult subject
anoth approach hiv cure also report natur week human patient exhibit hiv
remiss hematopoiet stem cell transplant donor cell carri hiv-resist
zfn technolog modifi gene hsc cell on-going effort produc similar
result engin variant
tng fp unrat plan initi trial person cancer vaccin march
fda commission scott gottlieb announc resign effect month march
unrat announc departur dr alessandro riva evp oncolog march
unrat report result provid program updat march
unrat report result announc dose ipsc-deriv product us march
page
announc dose first patient compani off-the-shelf induc pluripot
stem cell ipsc -deriv natur killer nk cell product februari evalu phase studi
advanc cancer monotherapi combin checkpoint inhibitor
importantli ipsc-deriv therapi dose human us compani also receiv
ind clearanc ipsc-deriv product nk cell product engin express non-cleav
fc receptor mediat antibody-depend cellular cytotox adcc
assess relapsed/refractori hematolog malign combin certain fda-approv
monoclon antibodi therapi genet engin ipsc-deriv product clear human test
unrat announc price mm public offer common stock march
buy report top-line result phase studi rnai tx givosiran ahp march
report result provid updat clinic preclin program across pipelin
compani submit protocol random phase ii trial person cancer vaccin candid
resect melanoma combin merck unrat keytruda number neoantigen
encod vaccin increas also announc ind open
intratumor deliv mrna encod evalu solid tumor
addit announc receiv track design fda system therapi
methylmalon acidemia program open ind phase i/ii trial pediatr patient previous
receiv pediatr diseas design orphan drug design fda ema
buy open manufactur facil pittsburgh pa success cgmp run march
tx privat rais mm seri advanc crispr base edit tx program march
ut sw publish correct exon delet dmd mice human cell via crispr march
 tennesse publish use car-t cell treat lupu mous model march
neutral report result provid corpor updat march
unrat publish vascular deliveri patient march
harvard/mgh publish review aav gt nervou system clinic applic march
unrat report result highlight recent progress march
mlmd mi unrat extend partnership genenta scienc privat ex vivo oncolog march
abu buy report result outlin recent progress guidanc march
cll unrat enter leas agreement build sq ft commerci manufactur facil march
cyad unrat appoint dr ann moor vice-president corpor strategi march
trvx-ose unrat receiv notic allow us patent mutant kra vaccin march
unrat announc public new zfn architectur improv target march
unrat report result outlin recent program highlight march
compani mention report
page
page
select catalyst genet medicin coverag
axo-lenti-pd report data first patient sunrise-pd phase i/ii trial
present data immun mechan action ovarian cancer
provid initi data phase trial tay-sachs/sandhoff diseas
dcr-phxc initi phase ii/iii primari hyperoxaluria pend regulatori feedback
file ind rett syndrom
provid program updat phase i/ii valen trial crigler-najjar syndrom
aro-aat initi phase ii/iii studi liver diseas
zolgensma provid clinic data readout strong phase studi sma type
zolgensma anticip regulatori decis sma type
present updat clinic data xlmtm
provid program overview undisclos larg neuromuscular diseas
select optim dose xlmtm
vy-aadc provid longer term data phase ib trial pd
nsr-rpgr provid follow-up data phase xiriu dose escal studi xlrp
report result piii revers trial result piii rescu trial lhon
file ind inherit amyotroph later sclerosi
file ind cta pomp diseas
initi phase i/ii trial autosom recess congenit ichthyosi
complet enrol dose escal phase i/ii trial achm
complet enrol phase iia studi wet
resum enrol phase i/ii studi hofh
dose patient phase trial gangliosidosi
provid earli data cohort phase i/ii pioneer trial n- rp
releas cgmp manufactur phase i/ii studi
initi phase i/ii trial
aav-rpgr prelim dose escal data phase i/ii trial xlrp
optogenet candid collab w/ bionic sight file ind advanc retin diseas
 fc report plan interim readout phase trial rhgg
initi trial malign
complet phase i/ii gem studi dystroph epidermolysi bullosa deb
complet ind-en studi diseas
dose patient phase studi mp
zolgensma anticip approv eu
lumasiran initi illuminate-b -c phase trial
givosiran complet nda applic file applic ahp
provid updat phase i/ii studi hemophilia
report phase i/ii data
provid prelim data phase i/ii patient defici
nsr-rpgr provid prelim data expans cohort phase ii/iii trial xlrp
figur expect zolgensma approv price anticip broad implic vivo gt space
page
select catalyst genet medicin coverag
file ind pomp diseas
submit ema lhon
nsr-rpgr report follow-up data open label dose escal phase xiriu studi
report interim efficaci readout phase oval trial ovarian cancer
report dose escal data pi/ii trial achm/xlrp
xlrp report interim data expans arm phase i/ii trial xlrp
file ind phase ii studi addit propos ophthalm indic
present interim data updat phase i/ii studi mp ii
present interim updat phase studi mp
present interim data cohort steroid prophyl pi/ii studi hofh
file ind batten diseas
initi phase trial dystroph epidermolysi bullosa deb
file ind ornithin transcarbamylas over-the-counter defici
provid initi data phase trial gangliosidosi
axo-aav-opmd initi clinic trial opmd phase specifi
report interim phase i/ii data rix nidcr/nih
initi dose phase trial hemophilia
dcr-hbv anticip first interim data clinic trial hbv
initi phase i/ii clinic trial huntington diseas
inclisiran report top-line data orion studi hypercholesterolemia
initi phase iib studi wet
lumasiran present top-line data illuminate-a phase trial
vutrisiran initi helios-b phase studi cardiomyopathi attr amyloidosi
inclisiran file nda hypercholesterolemia
updat dose escal pi/ii ignit trial dmd
cemdisiran initi phase ii studi iga nephropathi
initi phase i/ii trial
zolgensma complet strong phase trial pre-symptomat sma type
provid updat initi safeti studi hemophilia without inhibitor
 aro-enac file clear cell renal cell carcinoma cystic fibrosi
 fc initi phase ii/iii trial newli diagnos glioblastoma
 fc safeti activ readout phase ib trial met solid tumor
report preliminari data phase i/ii studi batten diseas
submit ind methylmalon acidemia mma
present preclin data new gt program fabri pomp defici
initi phase i/ii trial sjogren syndrom
file ind initi phase i/ii trial al
file ind initi phase i/ii trial wet
initi phase i/ii studi best diseas
 file ind al huntington diseas program
provid follow-up data piib dose-confirm studi hemb
present top-lin data phase i/iia clinic trial wet
initi pivot trial
 fc report final analysi phase trial rhgg
declar develop candid aml
figur alnylam/mdco meira gtx nightstar solid uniqur expect import data read-out
page
select catalyst outsid genet medicin coverag
figur plan file bla aadc defici
begin dose patient investigator-sponsor phase i/ii trial cystinosi
submit ind infantil batten diseas
report interim phase ii data recess dystroph epidermolysi bullosa
initi phase dose escal studi danon diseas
initi phase trial recess dystroph epidermolysi bullosa
 anticip data readout phase trial hd
initi phase ii trial multipl tumor type
begin patient dose phase trial
initi phase studi relapsed/refractori non-hodgkin lymphoma r/r nhl
aft spear cell report data phase trial hepatocellular carcinoma
initi clinic trial fanconi anemia use process product
submit ind gangliosidosi
initi pivot phase trial rdeb
dtx provid phase i/ii cohort data ornithin transcarbamylas defici
dtx provid pi/ii cohort data glycogen storag diseas type ia gsdia
valoctocogen roxaparvovec valrox provid pi/ii data updat hem
valrox present full piii top-line data hem
valrox submit bla pend fda feedback hemophilia
bmn file ind phenylketonuria pku
provid dystrophin data phase trial dmd
provid interim dystrophin data preclin studi dma
ptc-aadc file bla aromat l-amino acid decarboxylas aadc defici
initi phase ib trial beta-thalassemia
initi phase ii/iii trial dmd
ptc-fa file ind friedreich ataxia fa enter clinic
initi clinic trial charcot-marie-tooth type
lentiglobin initi phase studi sickl cell diseas
initi phase i/ii trial type gaucher diseas
file approv transit clinic trial platform manufactur
report data updat phase i/ii trial hemophilia
initi phase i/ii trial adult phenylketonuria
initi phase i/ii trial leukocyt adhes deficiency-i
rituximab report preliminari phase cohort expans data r/r nhl
sea-bcma report preliminari phase dose escal data r/r mm
micro-dystrophin initi pivot trial duchenn muscular dystrophi
hmaxi-k initi phase ii studi overact bladder
initi phase i/ii trial gangliosidosi
micro-dystrophin initi confirmatori trial commerci materi dmd
file ind applic multipl myeloma
tegsedi expect approv brazil hattr amyloidosi
page
corpor report factset chardan note mention stock unrat unless state select public gm compani includ adhera therapeut
benitec biopharma fibrocel buy lysogen oncosec medic oxford biomedica buy vbl neutral
figur select price movement week end march vivo gm perform aav srna ivg
page
week-over-week perform vivo genet medicin aav small rna vivo gene edit basketstickerratingccm ptupsideclosechang changemc mm genet medicin cap genet medicin vivo cap genet medicin ex vivo cap gene therapytickerratingccm ptupsideclosechang changemc mm nightstar genet rna therapytickerratingccm ptupsideclosechang changemc mm alnylam gene editingtickerratingccm ptupsideclosechang changemc mm logicbio pharmaceut
vivo genet medicin monthli market cap progress select compani
corpor report factset chardan note although avx acquir continu includ exhibit reflect valu creation sub-sector
figur aav-bas gene therapyend-monthli market cap select compani januari present
figur small rna therapyend-monthli market cap select compani januari present
figur vivo gene editingend-monthli market cap select compani januari present
page
cap million aav gt sector market cap cap million srna gt sector market cap cap million vivo gene edit sector market cap
aav-bas gene therapi comp meiragtx uniqur chardan top pick
corpor report factset chardan note mention stock unrat unless otherwis state target market cap uncov name model current market cap
refer partner product avexi novarti compani wet hofh mp mp ii phase i/ii trial
figur select public aav-bas gene therapi companiesw prefer buy buy qure buy greater potenti drive upsid aav gt space
page
targettargetccmphas ofpric ccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof genet technolog privat aav-bas genetherapi molecular ask estev horama stride tamid
small rna therapi comp alnylam top pick srna gene therapi offer favor risk-reward dynam
corpor report factset chardan note mention stock unrat unless state target market cap uncov name rgl model current market cap
figur select public small rna therapi companiesw prefer buy greater potenti drive upsid entir small rna space
page
targettargetccmphas ofpric ccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitalnylam privat small rna therapi companiesadvirna silense sirnaom somagen sylentisnot adhera benitec biopharma silenc addit unrat public compani
vivo gene edit comp see greater upsid potenti intellia toolgen
corpor report factset chardan note mention stock unrat unless otherwis state target market cap uncov name model current market cap
figur vivo gene editingw broadli expect out-performance crispr sector higher potenti perform buy toolgen buy
page
targettargetccmphas ofpric ccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitcrispr privat vivogen edit companiesbeam egenesi excis exon feldan poseida precis scienc recombinet
genet medicin therapeut approv posit opinion fda and/or ema
date
date
corpor report fda ema chardan note market author glybera expir due uniqur decis appli renew exclud antisens oligonucleotid figur
figur believ recent increas rate approv posit opinion genet medicin sign sector rapidli emerg
page
genet medicin therapeut receiv fda breakthrough therapi ema prime design
date fda btd
date ema prime
hattr amyloidosi polyneuropathi
corpor report fda ema biopharm insight chardan note ema start grant prime design may fda start grant breakthrough therapi design juli
figur believ disproportion amount btd prime design award genet medicin anoth sign sector rapidli emerg
page
date fda rmat
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur regen medicin advanc therapi design allow compani interact fda earlier clinic test process frequent
prioriti review voucher prv valu prv sold compani compani
date prv sale
ultragenyx undisclos
spark
ultragenyx novarti
biomarin undisclos
price prv
sarepta gilead
unit abbvi
sanofi
knight gilead
biomarin sanofi/regeneron pharmaceut
figur prioriti review voucher prv sold million million
page
date fda rpdd
corpor report fda biopharm insight chardan note list rpdd may incomplet sinc exampl compani disclos regulatori design
figur sinc pediatr diseas design potenti lead prioriti review voucher drug approv hidden sourc valu exist compani
page
date fda ftd
crispr vertex
rp due mutat exon gene
moder sever local scleroderma
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur track design facilit develop process expedit review drug seriou condit unmet medic need
page
genet medicin select therapeut receiv btd rmat prime rpdd and/or ftd us eu
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
genet medicin regulatori design btd rmat prime ftd rpdd grant time
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design ema start grant prime design may
fda start grant breakthrough therapi design btd juli pediatr diseas design rpdd rmat design genet medicin began novemb
figur regulatori design btd rmat prime ftd rpdd grant genet medicin consider increas grant
page
designationsyear design grantedgenet medicin regulatori design ytd btdrmatprimeftdrpdd biotechnolog pharmaceut
